Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 9.1 Form of Genome Voting Agreement
- 10.1 Security Agreement
- 10.2 Warrant to Purchase
- 10.3 Note Amendment and Exchange Agreement
- 10.4 Registration Rights Agreement
- 10.5 Promissory Note
- 23.1 Consent of Ernst & Young
- 23.2 Conset of Ernst & Young LLP
- 23.3 Consent of Ropes & Gray LLP
- 23.4 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP
- 23.5 Consent of Harris Nesbitt Corp.
- 99.4 Consent of Merrill Lynch, Pierce, Fenner & Smith Incorporated
OSCI similar filings
- 29 Mar 07 Registration of securities issued in business combination transactions (amended)
- 15 Mar 07 Registration of securities issued in business combination transactions
- 30 Dec 03 Registration of securities issued in business combination transactions (amended)
- 15 Dec 03 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.2
Consent of ERNST & YOUNG LLP, Independent Auditors
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 28, 2003 except for Note 12 as to which the date is November 17, 2003, included in the Proxy Statement of Genesoft Pharmaceuticals, Inc. that is made a part of the Registration Statement (Form S-4) and Prospectus of Genome Therapeutics Corp. for the registration of shares of its common stock.
/s/ ERNST & YOUNG LLP
Palo Alto, California
December 10, 2003